0
Products in the cart
Total:
Information block example
Currency
English Support
Request a call
Working hours:
Пн-Пт 9:00—23:00;
Сб-Вс 10:00-20:00

Erlotero 150mg

Erlotero 150mg (Erlotinib)

Erlotero tablet has active ingredient Erlotinib, used to treat non-small cell lung cancer, pancreatic cancer and other various types of cancer. Erlotero is pharmacologically categorized as tyrosine kinase inhibitor, acts on epidermal growth factor receptor.

Feature
Brand name:
Erlotero
Active substance:
Erlotinib 150mg
Manufacturer:
Hetero Drugs Ltd.
Packaging:
30 Tablets
Product form:
Tablet
In stock
Active substance: Erlotinib
0 $
Available options:
Amount:
To wishlist
Compared
Consulting:+91(994)0472902
Description

DESCRIPTION

Erlotero tablet has active ingredient Erlotinib, used to treat non-small cell lung cancer, pancreatic cancer and other various types of cancer. Erlotero is pharmacologically categorized as tyrosine kinase inhibitor, acts on epidermal growth factor receptor.

Erlotero tablets are prescription medicine, used only by the patients who have valid prescription

INDICATION

Erlotero is primarily indicated for; Non small cell lung cancer: Erlotero is considered as second, maintenance or greater line treatment in NSCLC. It is used after failure of some chemotherapy regimens. Erlotero is involved in the treatment of non-small cell lung cancer patients whose cancer cells containing epidermal growth factor receptors on their surface. Erlotero is not used in combination with platinum based compounds. In pancreatic carcinoma: In metastatic stage, Erlotero is used in combination with gemcitabine. In this condition Erlotero is involved as first line treatment.

PHARMACOLOGY

Erlotero has pharmacological effects like anti-tumor activity, which expels its action by prohibiting the intracellular phosphorylation of tyrosine kinase related with epidermal growth factor receptor. This EGFR is occurs on the surface of the tumor cells. Thus results as prohibition leads to intercede with signal transduction and lead to cell lyses.

ADME PROPERTY

ABSORPTION

The peak plasma concentration time reaches at 4 hours after drug intake After drug intake, the oral bioavailability of Erlotinib occurs as 60%, whereas a meal increases its bioavailability to 100%. The Erlotinib solubility is depends upon pH level. The reduction in solubility causes elevation of the pH levels. Smoking should be avoided during the treatment with Erlotero , causes decreasing the exposure of Erlotinib.

DISTRIBUTION

Volume of distribution of Erlotinib is 232L Human protein binding to Erlotinib is occurs as 93%.

METABOLISM

The metabolism of Erlotinib is occurs by CYP3A4

ELIMINATION

The route of elimination of Erlotinib metabolites occurs via; Feces: 83%; urine: 8% The terminal half life period of Erlotinib is 36.2 hours.

DOSAGE MANAGEMENT

DOSAGE MANAGEMENT

In NSCLC: The recommended dosage is 150mg should be taken as a single dose by administering on an empty stomach. In pancreatic cancer: The usual dosage of Erlotero is 100mg should be taken as a single dose by administering on an empty stomach by combining with gemcitabine. Dose alteration: In pulmonary toxicity: Interstitial lung disease, pulmonary failure: Discontinue the Erlotero therapy In severe hepatic failure: Stop the therapy permanently

In renal impairment: Discontinue the Erlotero therapy permanently In gastrointestinal perforation and severe diarrhea: Stop the therapy In severe Bullous and exfoliative skin disorders: Discontinue the therapy and provide supportive measures In corneal perforation, therapy should be discontinuing permanently. Avoid concomitant use of Erlotero with CYP3A4 strong inhibitors, CYP3A4 strong inducers, cigarette smoking, gastric regulators etc.

SIDE EFFECTS

SOME SERIOUS ADVERSE EFFECT

Renal failure Liver toxicity with failure Gastrointestinal perforations Ocular disorders Hemorrhage Bullous & exfoliative skin disorders Cerebrovascular disorders Hemolytic anemia & thrombocytopenia

SOME COMMON SIDE EFFECTS

Rash Diarrhea Cough Dyspnea Dry skin Back pain Conjunctivitis Mucosal inflammation Pruritus Paronychia Chest pain, arthralgia Musculoskeletal pain Myopathy like rhabdomyolysis while combining with lipid lowering drugs

DRUG INTERACTION

CYP3A4 INHIBITORS:
Concomitant use of Erlotero with CYP3A4 inhibitors like (boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketaconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit or grapefruit juice) causes increasing the exposure of Erlotinib. This result as increase in risk of adverse effects related to Erlotero .

IN CYP3A4 INDUCERS:
In combination of Erlotero with CYP3A4 inducers like anti-convulsants, rifampin, rifampicin, st Johns wort etc causes decreasing the exposure of Erlotinib. Thus results as decrease in therapeutic effect of Erlotero .

CYP1A2 INDUCERS & CIGARETTE SMOKING:
Both are decreasing the exposure of Erlotinib, while concomitant with Erlotero .

GASTRIC REGULATORS:
While concomitant with gastric regulators like proton pump inhibitors, H2 receptors antagonist or antacids, causes depletion of Erlotinib exposure leads to loss of therapeutic effect of Erlotinib.

ANTICOAGULANTS:
In combination of Erlotero with warfarin, causes increasing international normalized ratio & bleeding adverse reactions. To avoid this problem, monitor the prothrombin time frequently.

PRECAUTION

In interstitial lung disease: Severe pulmonary toxicity occurs, this may prevent by discontinue the therapy with Erlotero . Renal failure: To prevent this problem, patients should be monitored periodically with renal function test. On the other hand stop the therapy with Erlotero . Hepatic failure: Liver function test should be taken and monitored the patients frequently for any obstruction in liver functions. To avoid this complication, withhold or discontinue the therapy with Erlotero

In GI perforation: This condition occurs due to concomitant use of Erlotero with NSAIDS, taxane based chemotherapy agents, anti-angiogenic drugs, or corticosteroids etc. This is prevent by avoiding these combinations, or stop the treatment with Erlotero . Hemorrhage: To monitor the patient prothrombin time and INR during the therapy. This condition is majorly occurred due to combination of Erlotero with warfarin. Avoid this concomitant. Erlotero is not recommended in pregnancy period, this results as embryo fetal damage.

PREGNANCY & LACTATION

The pregnancy category of Erlotinib is D Erlotero tablets are not recommended for pregnancy conditions, because it may cause fetal harm even to death. Breast feeding should not be recommended.

CONTRAINDICATION

No contraindication occurs during Erlotero therapy. Some hypersensitivity reactions occur due to ingredients of Erlotero is contraindicated to the patients.

STORAGE

Erlotero should be stored at 25°C (77°F). Erlotero tablets should be keeping away from heat, light & moisture.

OVER DOSAGE

The over dosage of Erlotero is not possible in all conditions. If it may occurs, postpone or discontinue the Erlotero therapy and provide the patients with symptomatic therapy

MISSED DOSE

Erlotero is a chemo medicine, prescribed by medical oncologist. If patients fail to take the dose of Erlotero tablet, consult with physician and follow the instructions. On the other hand, the missed dose should be skipped and follow the regular dosing schedule.

Feature
Brand name
Erlotero
Active substance
Erlotinib 150mg
Manufacturer
Hetero Drugs Ltd.
Packaging
30 Tablets
Product form
Tablet
Strength
150mg
Erlotero 150mg отзывы
Add a comment
0

We use cookies to make the site better for you! Note: We strongly encourage you to talk with your health care professional about your specific medical condition and treatments. The information contained in this website is meant to be helpful and educati
Lorem Ipsum adalah text contoh digunakan didalam industri pencetakan dan typesetting. Lorem Ipsum telah menjadi text contoh semenjak tahun ke 1500an, apabila pencetak yang kurang terkenal mengambil sebuah galeri cetak dan merobakanya menjadi satu buku spe